Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.
about
The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpointsMHC-class-II are expressed in a subpopulation of human neural stem cells in vitro in an IFNγ-independent fashion and during development.Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significanceHDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escapeEpigenetic therapy for the treatment of epithelial ovarian cancer: A clinical reviewEpi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacyHistone deacetylase inhibitors as immunomodulators in cancer therapeutics.Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.Epigenetic modification and preliminary investigation of the mechanism of the immune evasion of HL-60 cells.Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.An extended genome-wide association study identifies novel susceptibility loci for nasopharyngeal carcinoma.Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study
P2860
Q26745842-B96048A6-AF07-4C41-9037-3CE4F5D45433Q27322541-4CA5911D-88CA-49E3-99B8-808F9482D234Q33970364-9117F864-0786-47EA-B61B-745C89C23202Q35176173-D32EEA41-A1A3-443C-B943-ADBC42AAE4BFQ37724905-79A14B7A-7D00-496E-8ABF-922FC849A43DQ38749824-52D884AA-17BD-4200-83F8-BB4EA23F6D6CQ38763747-373332D7-E432-4993-8E2E-309E7014BA42Q38988078-9421261C-7D3E-4D41-A8E0-EC805CAD0BE4Q39055861-BBF1A5EB-2843-4088-A0CC-55139BF7587AQ39201713-11A7CCEF-2D89-49D3-9903-092EF70E3EAAQ40890509-0F85DC92-AF47-4E46-A9CA-284CCB54DE45Q41279840-0AD7214F-8C74-4F73-BC16-C5B683CEB9A3Q46182440-EBFE208C-55EF-43B6-8728-FF183414242AQ51629770-73B5318A-2EC7-4640-B398-67A3A437650BQ57917353-161F3A21-E9C3-41C6-AD2B-165727C18A3B
P2860
Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Histone deacetylase inhibitors ...... diffuse large B-cell lymphoma.
@en
Histone deacetylase inhibitors ...... diffuse large B-cell lymphoma.
@nl
type
label
Histone deacetylase inhibitors ...... diffuse large B-cell lymphoma.
@en
Histone deacetylase inhibitors ...... diffuse large B-cell lymphoma.
@nl
prefLabel
Histone deacetylase inhibitors ...... diffuse large B-cell lymphoma.
@en
Histone deacetylase inhibitors ...... diffuse large B-cell lymphoma.
@nl
P2093
P2860
P356
P1433
P1476
Histone deacetylase inhibitors ...... diffuse large B-cell lymphoma.
@en
P2093
Daniel Persky
Kathleen Mulvaney
Kelly A Cycon
Lisa M Rimsza
Shawn P Murphy
P2860
P304
P356
10.1111/IMM.12136
P577
2013-10-01T00:00:00Z